Promoting symptom control in palliative care

Abrahm, Janet L.

doi:10.1016/s0749-2081(98)80015-6

Cited by 12 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in this case, other dimensions of pain such as duration, description, location or previous response to analgesics and other treatments may be overlooked. Abraham (1998) added that standard, validated assessment tools for pain and other symptoms need to be adopted by health care professionals and incorporated into routine monitoring and documentation.…”

Section: Pain Assessmentmentioning

confidence: 99%

Implementation of the pain and symptom assessment record (PSAR)

Bouvette

Fothergill‐Bourbonnais

Perreault

2002

Journal of Advanced Nursing

View full text Add to dashboard Cite

show abstract

Section: Pain Assessmentmentioning

confidence: 99%

Implementation of the pain and symptom assessment record (PSAR)

Bouvette

Fothergill‐Bourbonnais

Perreault

2002

Journal of Advanced Nursing

View full text Add to dashboard Cite

show abstract

“…25% to 30% of patients with recently diagnosed cancer suffer from pain. This rises as cancer progresses, so that 60% to 90% suffer pain at advanced stages 1–7 . Inadequately controlled pain can adversely impact on patients' lifestyles and relationships 8 .…”

Section: Introductionmentioning

confidence: 99%

The Role of OROS^Â®Hydromorphone in the Management of Cancer Pain

Gardner-Nix

Mercadante

2010

Pain Practice

View full text Add to dashboard Cite

The vast majority of cancer patients experience pain, and treatment with opioids offers the most effective option for pain management. Long-lasting opioid formulations are usually used as cancer pain management strategies. This review surveys the available literature on the only available once-daily sustained-release formulation of hydromorphone, and its use in cancer pain management. Sustained-release (SR) formulations have a more consistent opioid plasma concentration, thereby minimizing the peaks and troughs associated with immediate-release opioid formulations. OROS hydromorphone (Jurnista, Janssen Pharmaceuticals, NV, Beerse, Belgium) releases hydromorphone over a 24-hour dosing period. Studies comparing its efficacy with other opioids such as morphine and oxycodone found comparable results overall. Recent trials have provided evidence of decreased rescue medication use for breakthrough pain, a good safety profile, and quality of life benefits. It appears to be an efficacious and well-tolerated treatment. The pharmacokinetics of OROS hydromorphone are linear and dose-proportional, and only minimally affected by the presence or absence of food. In addition, the SR properties of OROS hydromorphone are maintained in the presence of alcohol, with no dose dumping of hydromorphone. This formulation shows promise as an addition to cancer pain management strategies, although further randomized, double-blind trials are needed to confirm this.

show abstract